Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
On August7, 2017, the Company entered into an amendment to the Offer Letter, dated as of May2, 2007 and amended on December23, 2008 and October9, 2009 (the “Offer Letter”), with Rudolf A. Baumgartner, M.D., the Executive Vice President, Chief Medical Officer of Inotek Pharmaceuticals Corporation (the “Company”) (the “Amendment”). Under the Amendment, in the event of a Change of Control (as defined in the Offer Letter), Dr.Baumgartner’s outstanding unvested equity awards will be fully vested upon his execution of a comprehensive release of claims in the Company’s favor.
The description of the Amendment set forth herein does not purport to be complete and is qualified in its entirety by reference to the full text thereof, which is attached hereto as Exhibit 10.1.
| Item 5.02 | Financial Statements and Exhibits. |
(d) Exhibits
|
Exhibit No. |
Description |
| 10.1 | Amendment to Offer Letter, effective as of August7, 2017, by and between the Company and Rudolf A. Baumgartner, M.D. |
* * *
INOTEK PHARMACEUTICALS CORP ExhibitEX-10.1 2 d435519dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 AMENDMENT TO OFFER LETTER This Amendment to the Offer Letter (this Amendment),…To view the full exhibit click here
About Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye’s trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.